

Yasuhiro Katsumata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7972820/publications.pdf>

Version: 2024-02-01

25
papers

1,216
citations

686830

13
h-index

642321

23
g-index

25
all docs

25
docs citations

25
times ranked

1217
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. <i>Rheumatology</i> , 2010, 49, 1713-1719.	0.9	261
2	Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. <i>Rheumatology</i> , 2012, 51, 1563-1570.	0.9	261
3	Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. <i>Rheumatology</i> , 2014, 53, 2196-2203.	0.9	153
4	Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. <i>Rheumatology</i> , 2010, 49, 1354-1360.	0.9	143
5	IL-6, IL-8, and IL-10 Are Associated with Hyperferritinemia in Rapidly Progressive Interstitial Lung Disease with Polymyositis/Dermatomyositis. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	67
6	Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. <i>Lancet Rheumatology</i> , The, 2019, 1, e95-e102.	2.2	65
7	Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e24-e30.	2.2	45
8	Role of innate immunity in a murine model of histidyl-tRNA synthetase (Jo1)-mediated myositis. <i>Arthritis and Rheumatism</i> , 2011, 63, 479-487.	6.7	44
9	Development of the Asia Pacific Lupus Collaboration cohort. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 425-433.	0.9	24
10	Reliability of the SF-36 in Japanese patients with systemic lupus erythematosus and its associations with disease activity and damage: a two-consecutive year prospective study. <i>Lupus</i> , 2018, 27, 407-416.	0.8	21
11	KL-6 is a long-term disease-activity biomarker for interstitial lung disease associated with polymyositis/dermatomyositis, but is not a short-term disease-activity biomarker. <i>Modern Rheumatology</i> , 2019, 29, 625-632.	0.9	18
12	“Not at target”: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, 70.	1.6	17
13	Usefulness of soluble CD163 as a biomarker for macrophage activation syndrome associated with systemic lupus erythematosus. <i>Lupus</i> , 2019, 28, 986-994.	0.8	15
14	Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases. <i>Journal of Rheumatology</i> , 2018, 45, 947-955.	1.0	14
15	COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1255-1257.	0.9	12
16	Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus. <i>Lupus</i> , 2019, 28, 1669-1677.	0.8	11
17	Clinical usefulness of anti-M-type phospholipase-A-receptor antibodies in patients with membranous nephropathy and the comparison of three quantification methods. <i>Immunological Medicine</i> , 2020, 43, 47-56.	1.4	9
18	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. <i>Rheumatology</i> , 2021, 60, 5185-5193.	0.9	9

#	ARTICLE	IF	CITATIONS
19	Validation of the Japanese version of the Systemic Lupus Activity Questionnaire that includes physician-based assessments in a large observational cohort. <i>Lupus</i> , 2016, 25, 486-495.	0.8	8
20	Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity. <i>Lupus</i> , 2020, 29, 686-696.	0.8	8
21	Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 2033-2041.	1.5	6
22	Tumour necrosis factor inhibitor-induced myositis in a patient with ulcerative colitis. <i>Modern Rheumatology Case Reports</i> , 2021, 5, 156-161.	0.3	3
23	Colonoscopy was useful for the diagnosis and the guidance of treatment escalation/de-escalation in a refractory case of lupus colitis. <i>Modern Rheumatology Case Reports</i> , 2018, 2, 30-32.	0.3	1
24	Validation of the Japanese version of the Lupus Damage Index Questionnaire in a large observational cohort: A two-year prospective study. <i>Modern Rheumatology</i> , 2020, 31, 1-9.	0.9	1
25	Comparisons between US norm-based two-component and Japanese norm-based three-component SF-36 summary scores in systemic lupus erythematosus patients. <i>Modern Rheumatology</i> , 0, , .	0.9	0